PROHANCE
Total Payments
$461,716
Transactions
74
Doctors
16
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $389,227 | 67 | 16 |
| 2018 | $52,475 | 5 | 0 |
| 2017 | $20,014 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $459,116 | 37 | 99.4% |
| Travel and Lodging | $1,381 | 9 | 0.3% |
| Food and Beverage | $1,219 | 28 | 0.3% |
Payments by Type
Research
$459,116
37 transactions
General
$2,600
37 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| THE SAFETY AND EFFICACY OF PROHANCE AT THE DOSE OF 0.10 MMOL/KG IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIENTS WHO ARE YOUNGER THAN 2 YEARS OF AGE | BRACCO DIAGNOSTICS INC. | $240,093 | 0 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | BRACCO DIAGNOSTICS INC. | $129,868 | 1 |
| INCIDENCE OF NEPHROGENIC SYSTEMIC FIBROSIS (NSF) IN PATIENTS WITH LOW EGFR RECEIVING GADOTERIDOL (PROHANCE) FOR CONTRAST-ENHANCED MRI | BRACCO DIAGNOSTICS INC. | $62,072 | 0 |
| INCREASING SPATIAL RESOLUTION OF CONTRAST-ENHANCED MR ANGIOGRAPHY:UTILIZING OPTIMIZED INJECTION PROFILES | BRACCO DIAGNOSTICS INC. | $20,345 | 0 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT | BRACCO DIAGNOSTICS INC. | $3,840 | 0 |
| A PROSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE OR PROHANCE IN COMPARISON WITH A CONTROL GROUP RECEIVING NO EXPOSURE TO GADOLINIUM | BRACCO DIAGNOSTICS INC. | $2,600 | 0 |
| HUNDLEY - PREVENTING ANTHRACYCLINE CARDIOVASCULAR TOXICITY WITH STATINS | BRACCO DIAGNOSTICS INC. | $297.62 | 0 |
Top Doctors Receiving Payments for PROHANCE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $457,196 | 36 |
| , M.D | Diagnostic Radiology | Madison, WI | $1,920 | 1 |
| , M.D | Diagnostic Radiology | Durham, NC | $1,523 | 20 |
| , M.D., PH.D | Diagnostic Radiology | Baltimore, MD | $311.41 | 4 |
| , MD | Neuroradiology | Los Angeles, CA | $142.70 | 1 |
| , MD | Diagnostic Radiology | Madison, WI | $105.03 | 1 |
| , M.D | Diagnostic Radiology | Durham, NC | $105.03 | 1 |
| Aytekin Oto | Diagnostic Radiology | Chicago, IL | $105.03 | 1 |
| , MD | Neuroradiology | East Lansing, MI | $105.03 | 1 |
| , M.D | Neuroradiology | Springfield, IL | $58.00 | 1 |
| , MD | Diagnostic Radiology | Omaha, NE | $42.00 | 1 |
| , MD PHD | Diagnostic Radiology | Madison, WI | $42.00 | 1 |
| , M.D | Diagnostic Radiology | Chicago, IL | $14.05 | 1 |
| , MD | Vascular & Interventional Radiology | Des Moines, IA | $14.04 | 1 |
| , MD | Diagnostic Radiology | Omaha, NE | $14.04 | 1 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $9.97 | 1 |
| Alessandro Furlan | Diagnostic Radiology | Pittsburgh, PA | $9.11 | 1 |
Ad
Manufacturing Companies
- BRACCO DIAGNOSTICS INC. $461,716
Product Information
- Type Drug
- Total Payments $461,716
- Total Doctors 16
- Transactions 74
About PROHANCE
PROHANCE is a drug associated with $461,716 in payments to 16 healthcare providers, recorded across 74 transactions in the CMS Open Payments database. The primary manufacturer is BRACCO DIAGNOSTICS INC..
Payment data is available from 2017 to 2019. In 2019, $389,227 was paid across 67 transactions to 16 doctors.
The most common payment nature for PROHANCE is "Unspecified" ($459,116, 99.4% of total).
PROHANCE is associated with 7 research studies, including "THE SAFETY AND EFFICACY OF PROHANCE AT THE DOSE OF 0.10 MMOL/KG IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIENTS WHO ARE YOUNGER THAN 2 YEARS OF AGE" ($240,093).